圣诺生物多款药品拟中选国家集采接续采购

Recent Events - The company announced on February 11, 2026, that its wholly-owned subsidiary, Chengdu Saintno Biological Pharmaceutical Co., Ltd., is participating in the national organized procurement of medicines, with multiple products (such as Acetate Octreotide Injection and Thymosin Alpha 1 Injection) expected to be selected. The results of the selection are anticipated to be officially implemented by the end of March 2026, with the procurement cycle lasting until the end of 2028. This event may impact future sales scale and market share [2]. Performance and Operations - The company released a profit forecast on January 16, 2026, indicating a significant year-on-year increase in net profit attributable to the owners of the parent company. However, specific financial data will be confirmed in the subsequent audited annual report, the release date of which has not yet been announced. Attention should be paid to official communications from the company [3].